Tocilizumab Treatment in COVID-19 Patients: Comparing Cutaneous Disease and Adverse Drug Effects.
Publication/Presentation Date
12-1-2023
Abstract
Actemra (tocilizumab) received emergency use authorization for the treatment of coronavirus disease 2019 (COVID-19) in June 2021. Literature has linked numerous cutaneous adverse effects to tocilizumab. In this current survey, investigators reviewed and compared these adverse effects to the common cutaneous manifestations of COVID-19. While similarities in patient presentation exist, important distinctions are made to aid dermatologists in their clinical diagnosis. J Drugs Dermatol. 2023;22(12):e42-e43. doi:10.36849/JDD.6532e.
Volume
22
Issue
12
First Page
42
Last Page
42
ISSN
1545-9616
Published In/Presented At
Rosenberg, A., Waller, J. D., Szeto, M. D., Pulsipher, K. J., Bloomfield, C. A., Presley, C. L., & Dellavalle, R. P. (2023). Tocilizumab Treatment in COVID-19 Patients: Comparing Cutaneous Disease and Adverse Drug Effects. Journal of drugs in dermatology : JDD, 22(12), e42–e43. https://doi.org/10.36849/JDD.6532
Disciplines
Medicine and Health Sciences
PubMedID
38051828
Department(s)
Department of Medicine, Department of Medicine Faculty, Department of Medicine Fellows and Residents, Fellows and Residents
Document Type
Article